Corey Williams

rss feed

Corey Williams's Latest Posts

BST Trade Alert: April 8, 2014

BST Trade Alert: April 8, 2014

| April 8, 2014

April 8, 2014 Recommendation: Buy Catalyst Pharmaceutical Partners (NASDAQ: CPRX) up to $2.30 About the Company: Catalyst is a development-stage biotech focused on developing drugs for rare neuro-muscular and neurological diseases. It currently has three drugs in development for the treatment of Lambert-Easton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. For purposes of this trade, we’re […]

Continue Reading

EOT trade alert April 4, 2014

EOT trade alert April 4, 2014

| April 4, 2014

April 4, 2014 Trade Alert: Buy APA May 2014 $85.00 Calls at $2.65 or better Company Background: Apache (APA) is an independent energy company. They explore, develop, and produce crude oil and natural gas liquids. Short-Term Catalyst: APA has been an underperforming stock over the last few years. They’ve been dogged by slow production growth […]

Continue Reading

EOT position update April 2, 2014

EOT position update April 2, 2014

| April 2, 2014

April 2, 2014 Market Snapshot The first quarter of 2014 hasn’t been great for the stock market.  The S&P 500 is up a mere 0.5%.  But it’s also within 1% of the all-time high.  So, it’s not the end of the world either. As the quarter comes to an end, there are some very important […]

Continue Reading

BST Special Position Update: April 2, 2014

BST Special Position Update: April 2, 2014

| April 2, 2014

April 2, 2014   ***Special Position Update***. . . . Prana Biotechnology (NASDAQ: PRAN) – Hold Shares of PRAN have plunged more than 75% over the past couple of days.  The stock is down after the biotech reported disappointing top-line results from the phase 2 trial of PBT2 in Alzheimer’s disease. The drug failed to […]

Continue Reading

SET Portfolio Update April 2014

SET Portfolio Update April 2014

| April 1, 2014

April 1, 2014 Due to the rapidly deteriorating market conditions, I’ve decided to sell all of our open ETF positions and invest in Bitcoin.  Because, you know, how can investing in an unregulated market for an invisible cryptocurrency not produce huge profits! April Fools!  Sorry, I couldn’t resist a chance to poke fun at Bitcoin. […]

Continue Reading

EOT position update March 26, 2014

EOT position update March 26, 2014

| March 26, 2014

March 26, 2014 Market Snapshot 2014 is shaping up to be very different than 2013 for the market… The days of all the sectors going up at the same time are a thing of the past.  Now the strength and weakness shifts from one sector to the next on a weekly or sometimes daily basis. […]

Continue Reading

EOT trade alert March 25, 2014

EOT trade alert March 25, 2014

| March 25, 2014

March 25, 2014 Trade Alert: Buy GMCR May 2014 $90 Puts at $3.10 or better Company Background: Keurig Green Mountain (GMCR) is a specialty coffee and coffeemaker business.  They specialize in at home individual coffee servings and are brewers. Short-Term Catalyst: GMCR has been on a wild ride over the last few months.  The stock […]

Continue Reading

BST Position Update: March 25, 2014

BST Position Update: March 25, 2014

| March 25, 2014

March 25, 2014 . . . . Cerus (NASDAQ: CERS) – Buy up to $6.60 CERS is our latest addition to the portfolio.  They’re developing the INTERCEPT Blood System which is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. While we have high expectations for CERS, the timing of our trade […]

Continue Reading

EOT position update March 19, 2014

EOT position update March 19, 2014

| March 19, 2014

March 19, 2014 Market Snapshot The S&P 500 is caught in a tug-of-war between good and bad news… On one side, there’s US economic data.  Better than expected readings on the US labor market, retail sales, and industrial production are pulling the market higher. On the other side, the Russian invasion of Ukraine’s Crimea region […]

Continue Reading

BST Trade Alert: March 19, 2014

BST Trade Alert: March 19, 2014

| March 19, 2014

March 19, 2014 Recommendation: Buy Cerus (NASDAQ: CERS) up to $6.60 per share. About the Company: Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety.  INTERCEPT is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The company has worldwide rights to INTERCEPT for […]

Continue Reading